Active

Psoriatic Arthritis

Active

Ankylosing Spondylitis

Moderate to Severe

Juvenile Idiopathic Arthritis

Non-Infectious

Intermediate, Posterior and Panuveitis

Active

Psoriatic Arthritis

Moderate to Severe

Hidradenitis Suppurativa

Gastroenterology

Moderate to Severe

Crohn's Disease

Moderate to Severe

Pediatric Crohn's Disease

Moderate to Severe

Ulcerative Colitis

Ophthalmology

Non-Infectious

Intermediate, Posterior and Panuveitis

The IL-23 inhibitor from AbbVie indicated for the treatment of moderate to severe plaque
psoriasis in adults who are candidates for systemic therapy or phototherapy1

For Healthcare
Professionals

Within its first year, SKYRIZI has reached >95% PREFERRED COVERAGE* FOR COMMERCIAL PATIENTS

95% Coverage Icon

>95%

National commercial health plan formulary status under the pharmacy benefit updated as of April 2020.2

If you have determined that SKYRIZI is the appropriate treatment, preferred coverage* could mean:

EXCEPTIONAL access

for patients

Standard PRIOR AUTHORIZATION (PA) and appeal processes

potential for one-time PA/appeal approval

Find SKYRIZI status by state with
the Formulary lookup tool

See which plans in your area include SKYRIZI on their preferred drug Formulary

    Formulary access for moderate to severe plaque psoriasis patients

    Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies. The health plans and/or pharmacy benefit managers listed here have not endorsed and are not affiliated with this material.

    Skyrizi is the #1 prescribed biologic in new and switching plaque psoriasis patients

    As of 9/2019. New patients defined as bio-naïve; switch patients
    defined as bio-experienced switching biologics. Source: Integrated
    Symphony Health (PatientSource) and IQVIA (NPA, NSP) through
    proprietary method on diagnosis classification.

    Encourage your patients to enroll in

    Skyrizi Complete logo
    Heart Icon

    One-to-one support

    Nurse Ambassadors

    Savings Card Icon

    Affordability:

    Commercially insured patients may pay as little as $5 per quarterly dose

    Access:

    No charge for eligible patients experiencing initial insurance delay or denial§

    *Formulary Definitions: Preferred/Step 1 means the product is placed on the plan’s preferred formulary. Non-preferred products require higher out-of-pocket cost or step edit, or are placed on a higher tier. First-line refers to a preferred or parity formulary status.

    Ambassadors do not provide medical advice and are trained to direct patients to speak with their healthcare professional about any treatment-related questions, including further referrals.

    Terms and Conditions apply. This benefit covers SKYRIZI. Eligibility: Available to patients with commercial prescription insurance coverage for SKYRIZI who meet eligibility criteria. Copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D, Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veteran’s Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be able to use the Skyrizi Complete Savings Card and patient must call Skyrizi Complete at 1.866.SKYRIZI to stop participation. Patients residing in or receiving treatment in certain states may not be eligible. Patients may not seek reimbursement for value received from the Skyrizi Complete program from any third-party payers. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. This is not health insurance.

    §Program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veteran’s Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be eligible to participate in program. Available to patients between the ages of 18-63 with commercial prescription insurance coverage who meet eligibility criteria. Eligibility: Patients must be diagnosed with moderate to severe plaque psoriasis, have a valid prescription for SKYRIZI and participate in a commercial insurance plan that has denied or not yet made a formulary decision for SKYRIZI. Once the patient’s insurance plan has made a formulary decision and established a process for reviewing coverage requests for SKYRIZI, continued eligibility for the program requires the submission of a Prior Authorization prior to the next scheduled dose and appeal of the coverage denial within 180 days. Program provides SKYRIZI at no charge to patients for up to 2 years or until they receive insurance coverage approval, whichever occurs earlier. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage.

    Stay up to date on the latest
    SKYRIZI news and information

    Email Icon

    Get SkyriziComplete

    Resources for your patients

    Checkmark Icon

    Helpful resources for your practice and your patients

    SKYRIZI resources

    Computer and Syringe Icon
    IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
    Indication

    SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

    Important Safety Information

    Infection

    SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

    In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

    Pre-Treatment Evaluation for Tuberculosis (TB)

    Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

    Immunizations

    Prior to initiating SKYRIZI, consider completion of all age appropriate immunizations according to current immunization guidelines.

    Avoid use of live vaccines in patients treated with SKYRIZI.

    Adverse Reactions

    Most common (≥1 %) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

    Please see Full Prescribing Information.

    US-SKZD-190350

    REFERENCES

    1. SKYRlZI [package insert]. North Chicago, IL: AbbVie Inc.
    2. Data on file, AbbVie Inc. MMIT-reported lives. 2020.
    3. Data on file, AbbVie Inc. In-play patient share. 2020.
    IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
    Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated. Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.
    IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
    Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves
    IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
    Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated. Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.
    IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
    Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves
    IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
    Indication

    SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

    Important Safety Information

    Infection

    SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

    In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

    Pre-Treatment Evaluation for Tuberculosis (TB)

    Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

    Immunizations

    Prior to initiating SKYRIZI, consider completion of all age appropriate immunizations according to current immunization guidelines.

    Avoid use of live vaccines in patients treated with SKYRIZI.

    Adverse Reactions

    Most common (≥1 %) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

    Please see Full Prescribing Information.

    US-SKZD-190350